Literature DB >> 8662883

Role of tetrahydrobiopterin availability in the regulation of nitric-oxide synthase expression in human mesangial cells.

M Saura1, D Pérez-Sala, F J Cañada, S Lamas.   

Abstract

Human mesangial cells express an inducible form of nitric-oxide synthase (iNOS) after treatment with cytokines. Tetrahydrobiopterin (BH4), an essential cofactor for NOS, is required for cytokine-induced NO generation. We report here that BH4 is necessary not only for the activity but also for the expression of iNOS in human mesangial cells. Inhibition of de novo BH4 synthesis with 2,4-diamino-6-hydroxypyrimidine (DAHP) significantly attenuated iNOS activity as well as mRNA and protein expression in response to interleukin 1beta plus tumor necrosis factor alpha (IL-1beta/TNF-alpha). In contrast, sepiapterin, which provides BH4 through the pterin salvage pathway, strongly potentiated IL-1beta/TNF-alpha-induced iNOS expression and abrogated the inhibitory effect of DAHP. Inhibition of the pterin salvage pathway with methotrexate abolished sepiapterin potentiation of iNOS induction but did not alter the effect of IL-1beta/TNF-alpha. Determination of intracellular pteridines confirmed that sepiapterin markedly raised BH4 content, an effect that was blocked by methotrexate. These results suggest that BH4 availability plays an important role in the regulation of iNOS expression. The effect of BH4 appears to be mediated, at least in part, by an increase in mRNA stability, as indicated by the observation that DAHP shortened, whereas sepiapterin prolonged the half-life of IL-1beta/TNF-alpha-induced iNOS mRNA. Taken together, our results suggest that the biosynthesis of BH4 contributes to cytokine induction of iNOS expression in human mesangial cells through the stabilization of iNOS mRNA.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8662883     DOI: 10.1074/jbc.271.24.14290

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

1.  Characterization of a constitutive type III nitric oxide synthase in human U937 monocytic cells: stimulation by soluble CD23.

Authors:  V Roman; N Dugas; A Abadie; C Amirand; H Zhao; B Dugas; J P Kolb
Journal:  Immunology       Date:  1997-08       Impact factor: 7.397

2.  Nitric oxide formation in acutely rejecting cardiac allografts correlates with GTP cyclohydrolase I activity.

Authors:  Galen M Pieper; Vani Nilakantan; Nadine L N Halligan; Ashwani K Khanna; Gail Hilton; Jeannette Vásquez-Vivar
Journal:  Biochem J       Date:  2005-11-01       Impact factor: 3.857

3.  Allosteric regulation of neuronal nitric oxide synthase by tetrahydrobiopterin and suppression of auto-damaging superoxide.

Authors:  P Kotsonis; L G Fröhlich; Z V Shutenko; R Horejsi; W Pfleiderer; H H Schmidt
Journal:  Biochem J       Date:  2000-03-15       Impact factor: 3.857

4.  Expression of nitric oxide synthase isoforms in pregnant human myometrium.

Authors:  S R Bartlett; P R Bennett; J S Campa; W J Dennes; D M Slater; G E Mann; L Poston; R Poston
Journal:  J Physiol       Date:  1999-12-15       Impact factor: 5.182

5.  Signalling mechanisms involved in the induction of inducible nitric oxide synthase by Lactobacillus rhamnosus GG, endotoxin, and lipoteichoic acid.

Authors:  Riku Korhonen; Riitta Korpela; Eeva Moilanen
Journal:  Inflammation       Date:  2002-10       Impact factor: 4.092

6.  Suppression of pathogen-inducible NO synthase (iNOS) activity in tomato increases susceptibility to Pseudomonas syringae.

Authors:  Meena R Chandok; Sophia K Ekengren; Gregory B Martin; Daniel F Klessig
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-14       Impact factor: 11.205

7.  The intracellular environment of human macrophages that produce nitric oxide promotes growth of mycobacteria.

Authors:  Joo-Yong Jung; Ranjna Madan-Lala; Maria Georgieva; Jyothi Rengarajan; Charles D Sohaskey; Franz-Christoph Bange; Cory M Robinson
Journal:  Infect Immun       Date:  2013-06-17       Impact factor: 3.441

8.  Nitric oxide modulators: an emerging class of medicinal agents.

Authors:  S R Deshpande; K Satyanarayana; M N A Rao; K V Pai
Journal:  Indian J Pharm Sci       Date:  2012-11       Impact factor: 0.975

9.  In vivo activation of AMP-activated protein kinase attenuates diabetes-enhanced degradation of GTP cyclohydrolase I.

Authors:  Shuangxi Wang; Jian Xu; Ping Song; Benoit Viollet; Ming-Hui Zou
Journal:  Diabetes       Date:  2009-06-15       Impact factor: 9.461

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.